Who is sponsoring NCT05710926?

NCT05710926 is sponsored by Tages Onlus.

What drugs are being tested in NCT05710926?

Interventions in NCT05710926: Evolutionary Systems Therapy for Schizotypy, Cognitive Behavioral Therapy.

What condition does NCT05710926 study?

NCT05710926 studies Schizotypal Personality Disorder.

Is NCT05710926 still recruiting?

NCT05710926 is currently status unknown. Last updated 6 July 2023.

Last reviewed 2023-07-06 · How we verify

NCT05710926: ESTS-RCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evolutionary Systems Therapy for Schizotypy

Status unknown NA Last updated 6 July 2023

What this trial tests

NA trial testing Evolutionary Systems Therapy for Schizotypy in Schizotypal Personality Disorder in 28 participants. Status unknown.

Timeline

5 October 2022

Primary endpoint
1 November 2024

1 January 2025

Quick facts

Lead sponsor	Tages Onlus
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	28
Start date	5 October 2022
Primary completion	1 November 2024
Estimated completion	1 January 2025
Sites	1 location across Italy

Drugs / interventions tested

Evolutionary Systems Therapy for Schizotypy
Cognitive Behavioral Therapy

Conditions studied

Schizotypal Personality Disorder — all drugs for Schizotypal Personality Disorder →

Sponsor

Tages Onlus

Who can join

18 and older, any sex, with Schizotypal Personality Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at replicating existing preliminary evidence about the effectiveness of Evolutionary Systems Therapy for Schizotypy (ESTS). The present randomized controlled trial (RCT) will compare ESTS with Cognitive Behavioral Therapy (CBT) in treating Schizotypal Personality Disorder (SPD). The main questions our RCT aims to answer are: 1. Is ESTS more effective than CBT in treating SPD? 2. Is ESTS more feasible than CBT in treating SPD? 38 patients diagnosed with SPD will be recruited and randomly allocated to either the experimental group (i.e. ESTS) or the control group (CBT). Primary outcome will be reduction in general symptomatology, whereas secondary outcomes will be changes in target mechanisms (self-criticism and metacognition) and remission from diagnosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tages Onlus trials

Trials by the same sponsor.

NCT06623838 — An Evolutionarily Informed Conceptualization of Personality Pathology · recruiting
NCT05700786 — Mindful Compassion for Perfectionism · NA · completed
NCT04764708 — Compassion and Metacognition in Schizotypal Personality · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05710926 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tages Onlus
Last refreshed: 6 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05710926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing